Table 4.
Biological enrichment analysis of experimentally validated target genes from the top 10 DEmiR from discovery analysis in all main cross-sectional study groups.
| Reactome—DaT-negative G2019S L2NMC | p value | Adj. p |
| Disinhibition of SNARE formation | 0.0009 | 1 |
| MECP2 regulates neuronal receptors and channels | 0.0093 | 1 |
| Response to elevated platelet cytosolic Ca2+ | 0.0103 | 1 |
| Regulation of KIT signaling | 0.0105 | 1 |
| Signaling by Rho GTPases | 0.0120 | 1 |
| Rho GTPase effectors | 0.0127 | 1 |
| Signaling by ERBB2 | 0.0130 | 1 |
| Innate immune system | 0.0140 | 1 |
| Antimicrobial peptides | 0.0153 | 1 |
| Axon guidance | 0.0196 | 1 |
| 166 user IDs/165 user IDs unambiguously mapped to 165 unique EntrezGene IDs/1 unmapped | ||
| Reactome—DaT-positive G2019S L2NMC | p value | Adj. p |
| Signaling by EGFR | 0.0104 | 1 |
| Collagen degradation | 0.0221 | 1 |
| Signaling by NOTCH1 | 0.0249 | 1 |
| Constitutive signaling by NOTCH1 | 0.0249 | 1 |
| Release of Hh-Np from the secreting cell | 0.0285 | 1 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex | 0.0285 | 1 |
| Removal of aminoterminal propeptides from γ-carboxylated proteins | 0.0354 | 1 |
| GAB1 signalosome | 0.0389 | 1 |
| RHO GTPases activate KTN1 | 0.0389 | 1 |
| γ-carboxylation, transport, and aminoterminal cleavage of proteins | 0.0389 | 1 |
| 65 user IDs/65 user IDs unambiguously mapped to 65 unique EntrezGene IDs | ||
| Reactome—G2019S L2PD | p value | Adj. p |
| Estrogen-dependent gene expression | 0.0006 | 0.5460 |
| ESR-mediated signaling | 0.0006 | 0.5460 |
| Signaling by nuclear receptors | 0.0013 | 0.7380 |
| Pre-NOTCH transcription and translation | 0.0048 | 0.8148 |
| RUNX1 genes/megakaryocyte differentiation and platelet function | 0.0052 | 0.8148 |
| RUNX1 regulated expression of components of tight junctions | 0.0057 | 0.8148 |
| RUNX1 regulated transcription of genes involved in interleukin signaling | 0.0057 | 0.8148 |
| Pre-NOTCH expression and processing | 0.0065 | 0.8148 |
| Senescence-associated secretory phenotype | 0.0066 | 0.8148 |
| Generic transcription pathway | 0.0067 | 0.8148 |
| 24 user IDs/24 user IDs unambiguously mapped to 24 unique EntrezGene IDs | ||
| Reactome—iPD | p value | Adj. p |
| Gene expression (transcription) | 7.25E−13 | 1.25E−09 |
| Generic transcription pathway | 2.16E−11 | 1.87E−08 |
| RNA polymerase II transcription | 9.32E−11 | 5.37E−08 |
| Transcriptional regulation by TP53 | 3.87E−08 | 1.67E−05 |
| Oncogene induced senescence | 4.89E−08 | 1.69E−05 |
| Signaling by TGF-beta family members | 3.80E−07 | 1.09E−04 |
| PIP3 activates AKT signaling | 5.40E−07 | 1.33E−04 |
| Circadian clock | 1.40E−06 | 3.02E−04 |
| Intracellular signaling by second messengers | 1.77E−06 | 3.05E−04 |
| Cellular responses to external stimuli | 1.95E−06 | 3.05E−04 |
| 1150 user IDs/1139 user IDs unambiguously mapped to 1139 unique EntrezGene IDs/11 unmapped | ||
DaT DaT-SPECT imaging, L2NMC LRRK2 non-manifesting carriers, L2PD LRRK2 carrier with symptomatic Parkinson disease, iPD idiopathic PD, Adj. p FDR multiple-test adjusted p value.